Clinical Trial Update: A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing mXELIRI plus bevacizumab to FOLFIRI plus bevacizumab as first-line therapy for metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• mXELIRI (mXELIRI)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED